Novo Cuts 11% of Workforce and Accelerates Efforts to Compete with Eli Lilly in the Obesity Market
Novo Nordisk announced plans to reduce its workforce by approximately 11%, as part of a broader strategy to accelerate its efforts in the obesity treatment market. The Danish pharmaceutical company…